22 Jul SmartCella
Ricardo Baptista, Ph.D., Chief Technology Officer
Oct. 6 | 5:45pm | FLW Ballroom F
Stockholm-Sweden
(Private)
SmartCella is a global biotech company pioneering targeted therapies through advanced delivery technologies and regenerative medicines. Its core segments—Targeted Delivery and Regenerative Medicines—translate scientific innovation into impactful clinical solutions. SmartCella’s proprietary Extroducer® is an endovascular device enabling precise delivery of therapeutics to hard-to-reach organs such as the heart, pancreas, lung, kidney, and brain. First used in humans in 2025 in a Phase IIb trial for refractory angina, it supports administration of gene and cell therapies, mRNA and biologics, radio-/chemotherapy, and small molecules. In regenerative medicine, SmartCella develops and manufactures off-the-shelf, allogeneic therapies derived from stem cells. Its pipeline includes SMART01 for heart failure, SMART02 for Parkinson’s disease, and SMART03, which uses an iMSC platform to deliver mRNA for cartilage regeneration in osteoarthritis. With several programs nearing clinical trials, including a pancreatic cancer study, SmartCella serves as a strategic translational partner to global biotech and pharmaceutical companies.
